<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; ACAD</title>
	<atom:link href="http://www.stockbloghub.com/tag/acad/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Sun, 20 May 2012 20:27:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(NBIX) Focus Turns To Biotech Next Week</title>
		<link>http://www.stockbloghub.com/2011/01/11/nbix-focus-turns-to-biotech-next-week/64740</link>
		<comments>http://www.stockbloghub.com/2011/01/11/nbix-focus-turns-to-biotech-next-week/64740#comments</comments>
		<pubDate>Tue, 11 Jan 2011 23:46:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Aastrom Biosciences Inc]]></category>
		<category><![CDATA[ACAD]]></category>
		<category><![CDATA[ACADIA Pharmaceuticals Inc]]></category>
		<category><![CDATA[ASTM]]></category>
		<category><![CDATA[Cytomedix Inc]]></category>
		<category><![CDATA[Cytori Therapeutics Inc]]></category>
		<category><![CDATA[CYTX]]></category>
		<category><![CDATA[DATA]]></category>
		<category><![CDATA[DATATRAK International Inc]]></category>
		<category><![CDATA[DEPO]]></category>
		<category><![CDATA[DepoMed Inc]]></category>
		<category><![CDATA[GTF]]></category>
		<category><![CDATA[NBIX]]></category>
		<category><![CDATA[Neurocrine Biosciences Inc]]></category>
		<category><![CDATA[Nile Therapeutics Inc]]></category>
		<category><![CDATA[NLTX]]></category>
		<category><![CDATA[OXBT]]></category>
		<category><![CDATA[Oxygen Biotherapeutics]]></category>
		<category><![CDATA[PBIO]]></category>
		<category><![CDATA[POZEN Inc]]></category>
		<category><![CDATA[POZN]]></category>
		<category><![CDATA[Pressure BioSciences Inc.]]></category>
		<category><![CDATA[SPEX]]></category>
		<category><![CDATA[Spherix Inc]]></category>
		<category><![CDATA[Transcept Pharmaceuticals Inc]]></category>
		<category><![CDATA[TSPT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=64740</guid>
		<description><![CDATA[Focus Turns To Biotech Next Week The week of January 10th is perhaps one of the biggest weeks in the biotechnology  industry. Three significant healthcare conferences will take place in San Francisco, headlined by the 29th annual J.P. Morgan Healthcare Conference held at the Westin St. Francis Hotel. The event is attended by the “Who’s Who” of the healthcare industry, with currently over 350 companies registered to attend. Two smaller conferences will also take place next week concurrent with the massive J.P. Morgan conference, the 4th annual OneMed Forum 2011 held at the Sir Francis Drake Hotel and the Biotech Showcase 2011 held at the Parc 55 Wyndham Hotel feature smaller companies from the biotech and medical device industries. These conferences are an outstanding opportunity for biotech investors to meet ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/01/11/nbix-focus-turns-to-biotech-next-week/64740/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACAD) Acadia Pharmaceuticals Gets Pimavanserin Back</title>
		<link>http://www.stockbloghub.com/2010/10/28/acad-acadia-pharmaceuticals-gets-pimavanserin-back/56947</link>
		<comments>http://www.stockbloghub.com/2010/10/28/acad-acadia-pharmaceuticals-gets-pimavanserin-back/56947#comments</comments>
		<pubDate>Thu, 28 Oct 2010 20:32:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACAD]]></category>
		<category><![CDATA[ACADIA Pharmaceuticals Inc]]></category>
		<category><![CDATA[ADP]]></category>
		<category><![CDATA[Automatic Data Processing Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=56947</guid>
		<description><![CDATA[This morning, Acadia Pharmaceuticals (ACAD) announced that it has entered into an agreement with Biovail Labs (BLS), a wholly owned subsidiary of Valeant Pharmaceuticals International, to conclude the previously established collaboration to develop and commercialize pimavanserin in the U.S. and Canada. Acadia has now reclaimed global rights to the drug. As part of the transaction, Biovail will pay Acadia a one-time payment of $8.75 million to terminate the agreement. No future payments between Acadia and BLS are expected. Acadia will push forward with the phase III-020 program testing pimavanserin as a treatment for Parkinson&#8217;s Disease Psychosis (PDP), a program that BLS was previously responsible for funding. Acadia initiated the trial in July 2010 with a target enrollment of 200 patients. Previously management estimated the costs of the program would be ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/28/acad-acadia-pharmaceuticals-gets-pimavanserin-back/56947/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BVF) Biovail and Acadia Pharmaceuticals Continue Forward with Pimavanserin Study</title>
		<link>http://www.stockbloghub.com/2010/03/10/bvf-biovail-and-acadia-pharmaceuticals-continue-forward-with-pimavanserin-study/30307</link>
		<comments>http://www.stockbloghub.com/2010/03/10/bvf-biovail-and-acadia-pharmaceuticals-continue-forward-with-pimavanserin-study/30307#comments</comments>
		<pubDate>Thu, 11 Mar 2010 02:31:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACAD]]></category>
		<category><![CDATA[ACADIA Pharmaceuticals Inc]]></category>
		<category><![CDATA[Biovail Corporation]]></category>
		<category><![CDATA[BVF]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30307</guid>
		<description><![CDATA[Biovail (BVF) and Acadia Pharmaceuticals (ACAD) are moving forward with a 3-pronged strategy for pimavanserin. Acadia plans a phase III trial in Parkinson’s disease psychosis (PDP) and a phase II feasibility study in Alzheimer’s disease psychosis (ADP). Biovail plans a phase III trial with pimavanserin as an adjunctive therapy for schizophrenia. All three programs should be up and running by the third quarter 2010. Management has made a number of changes to the planned third phase III program with pimavanserin PDP that we believe will aid in the success of the trial. Firstly, the trial will test only 40mg pimavanserin vs. placebo in a 1:1 randomization. We remind investors that the previous program had 3 arms at a 2:1 randomization (10mg and 40m vs. placebo). Reducing the randomization to 1:1 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/10/bvf-biovail-and-acadia-pharmaceuticals-continue-forward-with-pimavanserin-study/30307/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BVF) Biovail Corporation Continues with Pimavanserin</title>
		<link>http://www.stockbloghub.com/2009/10/16/bvf-biovail-corporation-continues-with-pimavanserin/17694</link>
		<comments>http://www.stockbloghub.com/2009/10/16/bvf-biovail-corporation-continues-with-pimavanserin/17694#comments</comments>
		<pubDate>Fri, 16 Oct 2009 21:49:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACAD]]></category>
		<category><![CDATA[ACADIA Pharmaceuticals Inc]]></category>
		<category><![CDATA[ADP]]></category>
		<category><![CDATA[Automatic Data Processing Inc]]></category>
		<category><![CDATA[Biovail Corporation]]></category>
		<category><![CDATA[BVF]]></category>
		<category><![CDATA[PDP]]></category>
		<category><![CDATA[PowerShares DWA Technical Leaders]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17694</guid>
		<description><![CDATA[Biovail Corporation (BVF) recently provided an update on its development plans for pimavanserin for Parkinson’s disease psychosis (PDP). The company is developing the candidate in collaboration with Acadia Pharmaceuticals, Inc. (ACAD) and stated that the partners remain committed towards the successful development of the candidate. In early Sept. 2009, the companies had reported results from a pivotal phase III study (-012 study) in which pimavanserin failed to meet its primary endpoint of antipsychotic efficacy due to an unexpectedly high placebo response rate. Based on an analysis of the data from this study, the partners have decided to continue with the development of the candidate. The companies intend to use findings from the -012 study and an ongoing phase III study (-014 study) for a new phase III trial. The new ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/16/bvf-biovail-corporation-continues-with-pimavanserin/17694/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

